Fleury Past Earnings Performance
Past criteria checks 5/6
Fleury has been growing earnings at an average annual rate of 14.7%, while the Healthcare industry saw earnings growing at 21.6% annually. Revenues have been growing at an average rate of 22.1% per year. Fleury's return on equity is 11.2%, and it has net margins of 8.1%.
Key information
14.7%
Earnings growth rate
4.0%
EPS growth rate
| Healthcare Industry Growth | 11.6% |
| Revenue growth rate | 22.1% |
| Return on equity | 11.2% |
| Net Margin | 8.1% |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
We Think Fleury's (BVMF:FLRY3) Profit Is Only A Baseline For What They Can Achieve
Nov 15
Concerns Surrounding Fleury's (BVMF:FLRY3) Performance
Mar 14Recent updates
Fleury's (BVMF:FLRY3) Dividend Is Being Reduced To R$0.2139
Dec 15We Think Fleury's (BVMF:FLRY3) Profit Is Only A Baseline For What They Can Achieve
Nov 15Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly
Nov 02Fleury S.A.'s (BVMF:FLRY3) Price Is Out Of Tune With Earnings
Sep 26We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt
Jun 18The Price Is Right For Fleury S.A. (BVMF:FLRY3)
Apr 16Concerns Surrounding Fleury's (BVMF:FLRY3) Performance
Mar 14Earnings Tell The Story For Fleury S.A. (BVMF:FLRY3)
Jan 05Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet
Oct 05Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?
Jun 27We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt
Feb 25At R$18.27, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?
Sep 26Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?
Sep 08Fleury (BVMF:FLRY3) Has Some Way To Go To Become A Multi-Bagger
Jul 01When Should You Buy Fleury S.A. (BVMF:FLRY3)?
Jun 10Is Fleury (BVMF:FLRY3) Using Too Much Debt?
Apr 10Return Trends At Fleury (BVMF:FLRY3) Aren't Appealing
Mar 24At R$19.12, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?
Feb 08Returns On Capital Are Showing Encouraging Signs At Fleury (BVMF:FLRY3)
Dec 08Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly
Nov 05Is Fleury S.A. (BVMF:FLRY3) Potentially Undervalued?
Oct 21Investors Should Be Encouraged By Fleury's (BVMF:FLRY3) Returns On Capital
Aug 24Fleury (BVMF:FLRY3) Seems To Use Debt Rather Sparingly
Jul 31Is It Time To Consider Buying Fleury S.A. (BVMF:FLRY3)?
Jul 07Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?
Apr 30Fleury (BVMF:FLRY3) Shareholders Will Want The ROCE Trajectory To Continue
Apr 12At R$25.16, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?
Mar 29Should You Or Shouldn't You: A Dividend Analysis on Fleury S.A. (BVMF:FLRY3)
Mar 16Only One Day Left To Cash In On Fleury's (BVMF:FLRY3) Dividend
Mar 01Fleury S.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28What Type Of Shareholders Make Up Fleury S.A.'s (BVMF:FLRY3) Share Registry?
Feb 15Shareholders of Fleury (BVMF:FLRY3) Must Be Delighted With Their 360% Total Return
Feb 02
Three Days Left To Buy Fleury S.A. (BVMF:FLRY3) Before The Ex-Dividend Date
Jan 03Should We Be Excited About The Trends Of Returns At Fleury (BVMF:FLRY3)?
Dec 28Would Fleury S.A. (BVMF:FLRY3) Be Valuable To Income Investors?
Dec 12Taking A Look At Fleury S.A.'s (BVMF:FLRY3) ROE
Nov 29Revenue & Expenses Breakdown
How Fleury makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 7,550 | 614 | 895 | 0 |
| 30 Jun 24 | 7,457 | 597 | 886 | 0 |
| 31 Mar 24 | 7,138 | 498 | 888 | 0 |
| 31 Dec 23 | 6,471 | 424 | 827 | 0 |
| 30 Sep 23 | 5,881 | 373 | 751 | 0 |
| 30 Jun 23 | 5,158 | 295 | 661 | 0 |
| 31 Mar 23 | 4,610 | 291 | 530 | 0 |
| 31 Dec 22 | 4,463 | 308 | 498 | 0 |
| 30 Sep 22 | 4,366 | 348 | 534 | 0 |
| 30 Jun 22 | 4,248 | 347 | 551 | 0 |
| 31 Mar 22 | 4,069 | 342 | 514 | 0 |
| 31 Dec 21 | 3,873 | 350 | 481 | 0 |
| 30 Sep 21 | 3,783 | 419 | 399 | 0 |
| 30 Jun 21 | 3,629 | 456 | 335 | 0 |
| 31 Mar 21 | 3,151 | 317 | 316 | 0 |
| 31 Dec 20 | 2,972 | 257 | 321 | 0 |
| 30 Sep 20 | 2,764 | 174 | 309 | 0 |
| 30 Jun 20 | 2,645 | 133 | 325 | 0 |
| 31 Mar 20 | 2,918 | 278 | 330 | 0 |
| 31 Dec 19 | 2,905 | 312 | 320 | 0 |
| 30 Sep 19 | 2,840 | 314 | 314 | 0 |
| 30 Jun 19 | 2,767 | 314 | 296 | 0 |
| 31 Mar 19 | 2,712 | 328 | 297 | 0 |
| 31 Dec 18 | 2,664 | 332 | 296 | 0 |
| 30 Sep 18 | 2,592 | 338 | 281 | 0 |
| 30 Jun 18 | 2,524 | 334 | 275 | 0 |
| 31 Mar 18 | 2,449 | 335 | 267 | 0 |
| 31 Dec 17 | 2,383 | 321 | 257 | 0 |
| 30 Sep 17 | 2,324 | 331 | 260 | 0 |
| 30 Jun 17 | 2,248 | 307 | 257 | 0 |
| 31 Mar 17 | 2,176 | 266 | 249 | 0 |
| 31 Dec 16 | 2,096 | 229 | 243 | 0 |
| 30 Sep 16 | 2,046 | 180 | 233 | 0 |
| 30 Jun 16 | 2,002 | 152 | 229 | 0 |
| 31 Mar 16 | 1,956 | 139 | 224 | 0 |
| 31 Dec 15 | 1,895 | 107 | 222 | 0 |
| 30 Sep 15 | 1,845 | 94 | 224 | 0 |
| 30 Jun 15 | 1,801 | 90 | 216 | 0 |
| 31 Mar 15 | 1,730 | 73 | 209 | 0 |
| 31 Dec 14 | 1,679 | 86 | 209 | 0 |
| 30 Sep 14 | 1,646 | 73 | 206 | 0 |
| 30 Jun 14 | 1,634 | 60 | 215 | 0 |
| 31 Mar 14 | 1,659 | 66 | 223 | 0 |
| 31 Dec 13 | 1,657 | 61 | 216 | 0 |
Quality Earnings: FLRY3 has high quality earnings.
Growing Profit Margin: FLRY3's current net profit margins (8.1%) are higher than last year (6.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FLRY3's earnings have grown by 14.7% per year over the past 5 years.
Accelerating Growth: FLRY3's earnings growth over the past year (64.3%) exceeds its 5-year average (14.7% per year).
Earnings vs Industry: FLRY3 earnings growth over the past year (64.3%) exceeded the Healthcare industry 64.3%.
Return on Equity
High ROE: FLRY3's Return on Equity (11.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 17:48 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fleury S.A. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fred Mendes | BofA Global Research |
| Flavio Yoshida | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |